GlassScriptPhysician profile
Sumiran Mehta
NPI 1841982550
$1,110.65
in general payments reported to CMS, 2019-2025
11 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $458 · 2024: $342 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.84 | 2023-2025 | Wegovy, Rybelsus |
| Genzyme Corporation | $268.23 | 2023-2024 | |
| Glaxosmithkline, LLC. | $143.02 | 2023 | Arexvy, Bexsero, Menveo |
| Amgen INC. | $124.99 | 2023 | Repatha |
| Abbvie INC. | $83.34 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.03 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.99 | 2025 | |
| Pharming Healthcare, INC. | $25.41 | 2025 | Ruconest |
| Averitas Pharma INC. | $22.27 | 2023 | Qutenza |
| Janssen Pharmaceuticals, INC | $22.03 | 2025 | Invega Sustenna |
| Phadia US INC. | $21.50 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumiran Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.